Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging

被引:43
|
作者
Werner, Rudolf A. [1 ,2 ]
Bundschuh, Ralph A. [3 ]
Bundschuh, Lena [3 ]
Javadi, Mehrbod S. [1 ]
Leal, Jeffrey P. [1 ]
Higuchi, Takahiro [2 ,4 ]
Pienta, Kenneth J. [5 ,6 ]
Buck, Andreas K. [2 ]
Pomper, Martin G. [1 ]
Gorin, Michael A. [1 ,5 ,6 ]
Lapa, Constantin [2 ]
Rowe, Steven P. [1 ,5 ,6 ]
机构
[1] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA
[2] Univ Hosp Wurzburg, Comprehens Heart Failure Ctr, Dept Nucl Med, Wurzburg, Germany
[3] Univ Med Ctr Bonn, Dept Nucl Med, Bonn, Germany
[4] Natl Cardiovasc & Cerebral Res Ctr, Dept Biomed Imaging, Suita, Osaka, Japan
[5] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA
[6] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA
基金
欧盟地平线“2020”; 美国国家卫生研究院;
关键词
F-18-DCFPyL; PSMA-RADS; interreader; interobserver; PSMA; prostate cancer; PROSTATE-CANCER; CLINICAL INTERPRETATION; F-18; RECURRENCE; PATTERNS; PEARLS;
D O I
10.2967/jnumed.118.217588
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Recently, the standardized reporting and data system for prostate-specific membrane antigen (PSMA)-targeted PET imaging studies, termed PSMA-RADS version 1.0, was introduced. We aimed to determine the interobserver agreement for applying PSMA-RADS to imaging interpretation of F-18-DCFPyL (2-(3-{1-carboxy-5-[(6-F-18-fluoro- pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET examinations in a prospective setting mimicking the typical clinical workflow at a prostate cancer referral center. Methods: Four readers (2 experienced readers (ERs,.3 y of PSMA-targeted PET interpretation experience) and 2 inexperienced readers (IRs,,1 y of experience)), who had all read the initial publication on PSMA-RADS 1.0, assessed 50 F-18-DCFPyL PET/CT studies independently. Per scan, a maximum of 5 target lesions was selected by the observers, and a PSMA-RADS score for every target lesion was recorded. No specific preexisting conditions were placed on the selection of the target lesions, although PSMA-RADS 1.0 suggests that readers focus on the most avid or largest lesions. An overall scan impression based on PSMA-RADS was indicated, and interobserver agreement rates on a target lesion-based, on an organ-based, and on an overall PSMA-RADS score-based level were computed. Results: The number of target lesions identified by each observer was as follows: ER 1, 123; ER 2, 134; IR 1, 123; and IR 2, 120. Among those selected target lesions, 125 were chosen by at least 2 individual observers (all 4 readers selected the same target lesion in 58 of 125 [46.4%] instances, 3 readers in 40 of 125 [32%], and 2 observers in 27 of 125 [21.6%]). The interobserver agreement for PSMA-RADS scoring among identical target lesions was good (intraclass correlation coefficient [ICC] for 4, 3, and 2 identical target lesions, >= 0.60, respectively). For lymph nodes, an excellent interobserver agreement was derived (ICC, 0.79). The interobserver agreement for an overall scan impression based on PSMA-RADS was also excellent (ICC, 0.84), with a significant difference for ER (ICC, 0.97) vs. IR (ICC, 0.74) (P 5 =.005). Conclusion: PSMA-RADS demonstrated a high concordance rate in this study, even among readers with different levels of experience. This finding suggests that PSMA-RADS can be effectively used for communication with clinicians and can be implemented in the collection of data for large prospective trials.
引用
收藏
页码:1857 / 1864
页数:8
相关论文
共 50 条
  • [1] Interobserver and intraobserver agreement in PET/CT with [18F]DCFPyL according to TNM molecular and PSMA-RADS 2.0 criteria
    Guerra-Gomez, Miriam
    Rodriguez-Pajuelo, Ana
    Brero-Sanchez, Laura
    Cuenca-Cuenca, Juan Ignacio
    Alvarez-Perez, Rosa Maria
    Freire-Macias, Jose Maria
    Garcia, Jose Manuel Jimenez-Hoyuela
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2024, 43 (05):
  • [2] Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients
    Freba Grawe
    Franziska Blom
    Michael Winkelmann
    Caroline Burgard
    Christine Schmid-Tannwald
    Lena M. Unterrainer
    Gabriel T. Sheikh
    Paulo L. Pfitzinger
    Philipp Kazmierczak
    Clemens C. Cyran
    Jens Ricke
    Christian G. Stief
    Peter Bartenstein
    Johannes Ruebenthaler
    Matthias P. Fabritius
    Thomas Geyer
    European Radiology, 2024, 34 : 1157 - 1166
  • [3] Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients
    Grawe, Freba
    Blom, Franziska
    Winkelmann, Michael
    Burgard, Caroline
    Schmid-Tannwald, Christine
    Unterrainer, Lena M.
    Sheikh, Gabriel T.
    Pfitzinger, Paulo L.
    Kazmierczak, Philipp
    Cyran, Clemens C.
    Ricke, Jens
    Stief, Christian G.
    Bartenstein, Peter
    Ruebenthaler, Johannes
    Fabritius, Matthias P.
    Geyer, Thomas
    EUROPEAN RADIOLOGY, 2023, 34 (2) : 1157 - 1166
  • [4] Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer
    Voter, Andrew F.
    Werner, Rudolf A.
    Pienta, Kenneth J.
    Gorin, Michael A.
    Pomper, Martin G.
    Solnes, Lilja B.
    Rowe, Steven P.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (07) : 681 - 694
  • [5] Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma
    Campbell, Scott P.
    Baras, Alexander S.
    Ball, Mark W.
    Kates, Max
    Hahn, Noah M.
    Bivalacqua, Trinity J.
    Johnson, Michael H.
    Pomper, Martin G.
    Allaf, Mohamad E.
    Rowe, Steven P.
    Gorin, Michael A.
    ANNALS OF NUCLEAR MEDICINE, 2018, 32 (01) : 69 - 74
  • [6] 18F-DCFPyL PET/CT guidelines
    Cardo, A. L. Gutierrez
    Casas, J. A. Vallejo
    Garzon, J. R. Garcia
    Hospital, J. L. Tirado
    Lopez, R. Medina
    Macias, J. M. Freire
    Fernandez, A. Rodriguez
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (03): : 203 - 208
  • [7] A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
    Rousseau, Etienne
    Wilson, Don
    Lacroix-Poisson, Frederic
    Krauze, Andra
    Chi, Kim
    Gleave, Martin
    McKenzie, Michael
    Tyldesley, Scott
    Goldenberg, S. Larry
    Benard, Francxois
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) : 1587 - 1593
  • [8] Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer
    Jansen, Bernard H. E.
    Jansen, Robin W.
    Wondergem, Maurits
    Srbljin, Sandra
    de Klerks, John M. H.
    Lissenberg-Witte, Birgit, I
    Vis, Andre N.
    van Moorselaar, Reindert J. A.
    Boellaard, Ronald
    Hoekstra, Otto S.
    Oprea-Lager, Daniela E.
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (02) : 210 - 216
  • [9] Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
    Wondergem, Maurits
    van der Zant, Friso M.
    Broos, Wouter A. M.
    Knol, Remco J. J.
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) : 1422 - 1429
  • [10] Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
    Pan, Ke-Hao
    Wang, Jin-Feng
    Wang, Chun-Ying
    Nikzad, Abdul Aziz
    Kong, Fang Q.
    Jian, Li
    Zhang, Yin-Qiu
    Lu, Xiao-Ming
    Xu, Bin
    Wang, Ya-Li
    Chen, Ming
    FRONTIERS IN ONCOLOGY, 2021, 10